Oral Drug Delivery Market Size, Share, Opportunities, And Trends By Formulation (Tablets, Capsules, Drops, Powder, Liquid Or Syrup, Decoction), By Application (Disease Treatment, Research/Academic Purposes), And By Geography – Forecasts From 2025 To 2030

Oral Drug Delivery Market Size:

The oral drug delivery market is forecasted to attain US$169.586 billion in 2030 at a CAGR of 4.83%, rising from US$133.944 billion in 2025.

Oral drug delivery is non-invasive, has a high rate of patient compliance, is easy to handle, and does not require any special sterile conditions; it is considered the most popular method of administration. Hence, it is highly preferred by a wide spectrum of patients. This drug delivery method is in high demand because of the prevalence of chronic diseases worldwide. Moreover, rising research and development investment, advancing health expenditure, and an aging population will all contribute to market expansion throughout the projection period.

________________________________________

Oral Drug Delivery Market Overview & Scope:

The oral drug delivery market is segmented by:

• Formulation: By formulation, the oral drug delivery market is categorized into tablets, capsules, drops, powder, liquid or syrup, and decoction. The tablet category is estimated to grow greatly as they are among the most common and easy-to-use formulations for oral drug delivery. Tablets also ensure a lower cost of formulation, with enhanced patient compliance. 
• Application: By application, the market is divided into disease treatment and research/academic purposes. The disease treatment category is estimated to grow significantly. The increasing prevalence of various acute and chronic diseases is the major factor propelling this category’s expansion. 
• Region: The Asia Pacific region is growing considerably during the forecasted timeline. The growing geriatric population in the region, especially in countries like Japan, South Korea, and Taiwan, are propelling this growth. Similarly, the increasing prevalence of chronic diseases is also among the key factors pushing the regional market expansion. 

________________________________________

Top Trends Shaping the Oral Drug Delivery Market

• Growing R&D investment

The growing advancements in drug delivery technology and increasing investment in research and development in the pharmaceutical sector are among the key factors pushing the market expansion. 

________________________________________

Oral Drug Delivery Market Growth Drivers vs. Challenges

Opportunities:

• Increase in the cases of chronic diseases: The increasing cases of chronic diseases worldwide are among the key factors pushing the global oral drug delivery market growth. Oral drug delivery offers a convenient and painless mode of drug delivery for patients suffering from chronic diseases, including cardiovascular diseases, cancer, and diabetes, among others. It also features lower patient supervision and lower cost of care. The global cases of chronic diseases, especially the cases of diabetes, witnessed a major increase. Diabetes UK, in its report, stated that during 2022-23, the total number of diabetes cases in the nation was recorded at 4.4 million. 
• Growing global geriatric population: The increasing population of geriatrics worldwide is another factor boosting this market’s growth. With the growing age, the cases of diseases like diabetes, neurological disorders, and cardiovascular diseases increase significantly. This highlights the necessity for an effective and efficient drug delivery system, which significantly requires lower supervision. The global population above the age of 65 years witnessed a major increase in the past few years. The World Bank, in its global report, stated that in 2022, the total population above the age of 65 years was recorded at 778.122 million, which surged to 804,475 million in 2023. 

Challenges:

• Growing cases of patient-centric problems: The increasing patient-centric issues, such as adherence and difficulties in swallowing, are among the key factors challenging the market expansion. 

________________________________________

Oral Drug Delivery Market Regional Analysis:

• North America: North America is expected to hold a large market share. Technological advances, rising patent approvals, and research on the usage of nanotechnology for drug delivery in the region are expected to drive the market. Furthermore, due to the rapid adoption of new drug delivery technologies and the presence of research centers developing innovative drug delivery systems in the country, the United States is expected to hold a significant share of the oral drug delivery systems market during the forecast period.

________________________________________

Oral Drug Delivery Market Competitive Landscape

The market is fragmented, with many notable players, including Pfizer Inc., AstraZeneca, Alpex Pharma S.A., SPI Pharma, Globela Pharma Pvt Ltd., Lupin Pharmaceuticals, Inc., Mayne Pharma Group Limited, Adare Pharmaceuticals, Inc., AdhexPharma, Aquestive Therapeutics, RAUMEDIC, and Croda International Plc, among others. 

• Product Launch: In September 2024, Evonik Industries, a global leader in specialty chemicals, launched EUDRACAP color functional capsules, which are specially designed for the targeted delivery of oral drugs. 

________________________________________

Oral Drug Delivery Market Scope:

Report Metric	Details
Oral Drug Delivery Market Size in 2025	US$133.944 billion
Oral Drug Delivery Market Size in 2030	US$169.586 billion
Growth Rate	CAGR of 4.83%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Formulation Application Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Oral Drug Delivery Market	Pfizer Inc. AstraZeneca Alpex Pharma S.A. SPI Pharma Globela Pharma Pvt Ltd.
Customization Scope	Free report customization with purchase

 

Oral Drug Delivery Market Segmentation: 

• By Formulation
  • Tablets
  • Capsules
  • Drops
  • Powder
  • Liquid or Syrup
  • Decoction
• By Application
  • Disease Treatment
  • Research/Academic purposes
• By Region
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Our Best-Performing Industry Reports:

• Drug Delivery System Market
• Small Molecule Drug Discovery Market
• Drug Delivery Market

---

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. ORAL DRUG DELIVERY MARKET BY FORMULATION

5.1. Introduction

5.2. Tablets

5.3. Capsules

5.4. Drops

5.5. Powder

5.6. Liquid or Syrup

5.7. Decoction

6. ORAL DRUG DELIVERY MARKET BY APPLICATION

6.1. Introduction

6.2. Disease Treatment

6.3. Research/Academic purposes

7. ORAL DRUG DELIVERY MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. By Formulation

7.2.2. By Application

7.2.3. By Country

7.2.3.1. USA

7.2.3.2. Canada

7.2.3.3. Mexico

7.3. South America

7.3.1. By Formulation

7.3.2. By Application

7.3.3. By Country

7.3.3.1. Brazil

7.3.3.2. Argentina

7.3.3.3. Others

7.4. Europe

7.4.1. By Formulation

7.4.2. By Application

7.4.3. By Country

7.4.3.1. United Kingdom

7.4.3.2. Germany

7.4.3.3. France

7.4.3.4. Spain

7.4.3.5. Others

7.5. Middle East and Africa

7.5.1. By Formulation

7.5.2. By Application

7.5.3. By Country

7.5.3.1. Saudi Arabia

7.5.3.2. UAE

7.5.3.3. Others

7.6. Asia Pacific

7.6.1. By Formulation

7.6.2. By Application

7.6.3. By Country

7.6.3.1. China

7.6.3.2. Japan

7.6.3.3. India

7.6.3.4. South Korea

7.6.3.5. Taiwan

7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Pfizer Inc.

9.2. AstraZeneca

9.3. Alpex Pharma S.A.

9.4. SPI Pharma

9.5. Globela Pharma Pvt Ltd.

9.6. Lupin Pharmaceuticals, Inc.

9.7. Mayne Pharma Group Limited

9.8. Adare Pharmaceuticals, Inc.

9.9. AdhexPharma

9.10. Aquestive Therapeutics

9.11. RAUMEDIC

9.12. Croda International Plc

10. APPENDIX

10.1. Currency 

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key benefits for the stakeholders

10.5. Research Methodology 

10.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Pfizer Inc.

AstraZeneca

Alpex Pharma S.A.

SPI Pharma

Globela Pharma Pvt Ltd.

Lupin Pharmaceuticals, Inc.

Mayne Pharma Group Limited

Adare Pharmaceuticals, Inc.

AdhexPharma

Aquestive Therapeutics

RAUMEDIC

Croda International Plc